Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Merck & Co., Inc. (MRK) — XLV Health Care · S&P 500 Profile |默克公司介紹

health-careS&P500xlvxlv-top-25
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Merck & Co., Inc. (MRK) — Business, History & S&P 500 Profile |默克公司介紹

Merck company profile · business segments · history · financial snapshot · S&P 500 rank #30 · 默克公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Oct 23, 2026 (ET) close
Financials: FY2025 (ended Dec 31, 2025)
MARKET CAP
≈$358B
As of Oct 23, 2026
S&P 500 WEIGHT
0.52%
Rank #30 · Oct 23, 2026
FY2025 SALES
$65.011B
FY2025 · ended Dec 31, 2025
FY2025 NET INCOME
$18.254B
Attributable to Merck & Co., Inc. · FY2025

SNAPSHOT

TickerMRK (NYSE)
CompanyMerck & Co., Inc.
GICS sector / industryHealth Care (XLV) / Pharmaceuticals
S&P 500 rank (by weight)#30 · 0.52% (Oct 23, 2026)
Sector rank (by weight)#5 of 60 in Health Care (Oct 23, 2026)
HeadquartersRahway, New Jersey (126 East Lincoln Avenue)
Founded1891, New York
CEORobert M. Davis (chairman, chief executive officer and president)
EmployeesApproximately 75,000 worldwide, including approximately 30,000 in the U.S. (Dec 31, 2025, FY2025 10-K)
Market cap≈$358B (Oct 23, 2026)
SEC filingsEDGAR — CIK 0000310158

WHAT IT DOES

Merck & Co., Inc. is a global health care company that delivers innovative health solutions through prescription medicines, including biologic therapies, vaccines and animal health products. Its one-line model: discover, develop and sell patent-protected prescription medicines and vaccines, led by oncology, and use the cash they generate to fund the next generation of medicines.

Merck & Co., Inc. (US, NYSE: MRK) is distinct from Merck KGaA (Germany). The two companies are separate companies with separate ownership, operations and financial results, and they share only a historical name origin. Outside the United States and Canada, Merck & Co., Inc. operates under the name MSD. All figures in this profile are for Merck & Co., Inc. only.

The commercial engine is the Pharmaceutical segment, which sells human health pharmaceutical and vaccine products, mainly by prescription, to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. Its largest product by far is Keytruda, an anti-PD-1 cancer therapy, with FY2025 sales of $31.68B. The second reported segment, Animal Health, sells veterinary pharmaceuticals, vaccines and digitally connected identification, traceability and monitoring products for livestock and companion animals.

Revenue is therefore concentrated in a small number of patented products, and the business model depends on replacing sales lost to patent expiry with new approvals and acquisitions. In FY2025 the company completed the acquisition of Verona Pharma, paying $10.042B in cash net of cash acquired, gaining a marketed treatment for chronic obstructive pulmonary disease.

BUSINESS SEGMENTS — FY2025

SegmentSalesShare
Pharmaceutical$58.142B89.4%
Animal Health$6.354B9.8%
Other revenues$0.515B0.8%
Total$65.011B100%
Source: Merck FY2025 Form 10-K (fiscal year ended Dec 31, 2025). Segment sales plus other revenues equal total sales. Other revenues are mainly miscellaneous corporate revenues, including revenue hedging activities and third-party manufacturing arrangements.

Pharmaceutical ($58.142B, 89.4% of total sales). Human health pharmaceutical and vaccine products, led by Keytruda at $31.68B and Gardasil/Gardasil 9 at $5.233B in FY2025. Oncology, vaccines, cardiometabolic and other therapeutic areas sit inside this segment.

Animal Health ($6.354B, 9.8% of total sales). Veterinary pharmaceuticals and vaccines, plus health management solutions and services, for livestock and companion animals. Within the segment, livestock sales were $3.896B in FY2025 on the product-sales table in the 10-K, with the balance in companion animals; those two product lines are shown here only as context, not as a second segment split.

HISTORY

YearMilestone
1891Established in New York as the United States business associated with the German Merck enterprise
1919Repurchased by George Merck after seizure by the United States government during World War I, becoming an independent American company
1953Merged with Sharp & Dohme, forming Merck Sharp & Dohme
2004Vioxx withdrawn from the market worldwide after safety concerns, a major reputational and financial setback
2009Completed the merger with Schering-Plough in November, keeping the Merck name
2014Keytruda (pembrolizumab) approved by the United States Food and Drug Administration, first for melanoma
2021Robert M. Davis becomes chief executive officer in July, succeeding Kenneth Frazier
2025Keytruda Qlex, a subcutaneous formulation of Keytruda, approved by the United States Food and Drug Administration in September across most adult solid tumor indications for Keytruda
2025Completed the acquisition of Verona Pharma in October

COMPETITIVE POSITION

  • Oncology leadership, with concentration. Keytruda sales of $31.68B in FY2025 made it one of the largest-selling medicines in the world, and the anchor of Merck's oncology franchise. Its main immuno-oncology rival is Bristol Myers Squibb's Opdivo.
  • Vaccines breadth. Gardasil/Gardasil 9, ProQuad/M-M-R II/Varivax and pneumococcal vaccines give Merck a large preventive-care franchise, even though Gardasil sales fell sharply in FY2025.
  • Scale in research. Research and development spending of $15.789B in FY2025, across oncology, vaccines, cardiometabolic, respiratory and infectious disease, supports a large late-stage pipeline, including combinations built around Keytruda.
  • Acquisition-led renewal. The $10.042B Verona Pharma acquisition in FY2025 is part of a deliberate pattern of buying marketed or late-stage assets to offset future patent losses, rather than relying only on internal discovery.
  • Competition set. Pfizer, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson and Amgen in prescription medicines and oncology; Zoetis and Boehringer Ingelheim in animal health.

FINANCIAL SNAPSHOT — FY2025

Sales$65.011B (+1.3% vs FY2024)
Cost of sales$16.382B
Gross profit$48.629B · 74.8% margin
Research and development$15.789B
Selling, general and administrative$10.733B
Income before taxes$21.067B
Net income attributable to Merck & Co., Inc.$18.254B · 28.1% margin
Operating cash flow$16.472B
Capital expenditures$4.112B
Cash and cash equivalents$14.565B (Dec 31, 2025)
Long-term debt$46.750B (Dec 31, 2025)
Source: Merck FY2025 Form 10-K (fiscal year ended Dec 31, 2025, filed Feb 24, 2026). Gross profit is sales less cost of sales. Latest quarter: Not available as a verified 10-Q figure in this draft; the third quarter of 2026 was scheduled to be reported on Oct 29, 2026, after the Oct 23, 2026 market-data as-of date.

KEY RISKS

  • Keytruda concentration and patent expiry. Keytruda/Keytruda Qlex sales of $31.68B were 48.7% of FY2025 total sales. The 10-K states that biosimilar competition could begin in December 2028 when the primary United States compound patent expires, and that Merck expects to lose market exclusivity in Europe in 2031 following compound patent expiration.
  • Government price setting. The 10-K states that Merck expects Keytruda to be selected in 2027 for government price setting, with the set price effective Jan 1, 2029, and that United States sales of Keytruda would decline materially after that time.
  • Gardasil decline. Gardasil/Gardasil 9 sales fell to $5.233B in FY2025 from $8.583B in FY2024, a 39% decline, showing how quickly a vaccine franchise can move on demand and inventory patterns.
  • Januvia and Janumet loss of exclusivity. The 10-K states that following loss of market exclusivity in May 2026, Merck anticipates it will lose nearly all United States sales of Januvia and Janumet.
  • Pipeline and deal execution. Replacing Keytruda-scale sales depends on late-stage trials, regulatory approvals and acquired assets performing as expected; the Verona Pharma acquisition alone cost $10.042B in cash net of cash acquired in FY2025.
  • Litigation and regulation. As a large prescription-medicine maker, Merck faces patent litigation, product-liability claims, pricing pressure and changing health-care regulation in the United States and abroad.

WHY IT MATTERS FOR THE S&P 500

Merck is a Health Care (XLV) constituent ranked #30 in the S&P 500 by weight at 0.52%, and #5 of 60 in Health Care, as of Oct 23, 2026. At that weight, a 1% move in MRK alone moves the S&P 500 by roughly 0.5 basis points before any read-through to pharmaceutical peers, so Merck is a sector bellwether rather than an index driver.

For index watchers, Merck matters in a different way: it is one of the largest pure pharmaceutical names in the index, so its Keytruda cycle, vaccine demand and patent-expiry calendar are read as signals for the whole Health Care sector, for drug-pricing policy, and for how much of the index's earnings growth is tied to a single patented product.

SOURCES & METHODOLOGY

Financials, segments, employees, headquarters, CEOMerck FY2025 Form 10-K (filed Feb 24, 2026; fiscal year ended Dec 31, 2025)
Index weight & ranksSlickcharts S&P 500 weights, Oct 23, 2026 close, as given in the dispatch baseline
Keytruda patent and price-setting statementsMerck FY2025 Form 10-K, Item 1 and Item 7 risk and patent disclosures
History milestonesCompany history as reported in established secondary coverage; 2009 merger and 2014 Keytruda approval are widely reported public events
LogoSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics.
Market cap≈$358B (Oct 23, 2026)

Price Chart — 10-Year Monthly Candles

MERCK

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號MRK(NYSE)
公司Merck & Co., Inc.(默克)
GICS 板塊/行業醫療健康(XLV)/製藥
標普500排名(按權重)#30 · 0.52%(2026年10月23日)
板塊內排名(按權重)醫療健康 #5 of 60(2026年10月23日)
總部新澤西州拉威(126 East Lincoln Avenue)
成立1891年,紐約
執行長Robert M. Davis(董事長、首席執行官兼總裁)
員工全球約75,000名,其中美國約30,000名(2025年12月31日,FY2025 10-K)
市值≈$358B(2026年10月23日)
SEC 申報EDGAR — CIK 0000310158

業務概覽

默克是一家全球醫療健康公司,透過處方藥(包括生物製劑)、疫苗與動物健康產品提供創新健康方案。一句話商業模式:發現、開發並銷售受專利保護的處方藥與疫苗,以腫瘤藥為首,再用其現金流資助下一代藥物。

Merck & Co., Inc.(美國,NYSE:MRK)與 Merck KGaA(德國)不同。兩家公司是各自獨立的公司,擁有權、營運與財務結果各不相同,僅有歷史名稱淵源。在美國與加拿大以外,Merck & Co., Inc. 以 MSD 之名營運。本篇所有數字皆僅屬 Merck & Co., Inc.。

商業引擎是製藥板塊,銷售人類健康處方藥與疫苗產品,主要經處方銷售給藥品批發商與零售商、醫院、政府機構與管理式醫療機構。其最大產品是抗 PD-1 癌症療法 Keytruda,FY2025 銷售額為 $31.68B(316.8億美元)。第二個申報板塊動物健康,則銷售獸用藥品、疫苗,以及用於牲畜與伴侶動物的數位連結識別、追溯與監測產品。

因此收入集中於少數專利產品,業務模式取決於以新批准與收購取代專利到期後失去的銷售。FY2025 公司完成了 Verona Pharma 收購,扣除取得現金後以現金支付 $10.042B(100.42億美元),取得一款慢性阻塞性肺病上市治療藥物。

業務板塊 — FY2025

板塊銷售額佔比
製藥$58.142B(581.42億美元)89.4%
動物健康$6.354B(63.54億美元)9.8%
其他收入$0.515B(5.15億美元)0.8%
合計$65.011B(650.11億美元)100%
來源:Merck FY2025 Form 10-K(會計年度截至2025年12月31日)。板塊銷售額加其他收入等於總銷售額。其他收入主要為雜項公司收入,包括收入對沖活動與第三方製造安排收入。

製藥($58.142B(581.42億美元),佔總銷售額 89.4%)。人類健康處方藥與疫苗產品,以 Keytruda $31.68B(316.8億美元)與 Gardasil/Gardasil 9 $5.233B(52.33億美元)為首(FY2025)。腫瘤、疫苗、心臟代謝及其他治療領域皆屬此板塊。

動物健康($6.354B(63.54億美元),佔總銷售額 9.8%)。獸用藥品與疫苗,以及健康管理方案與服務,服務牲畜與伴侶動物。板塊內牲畜銷售額在 10-K 產品銷售表中為 $3.896B(38.96億美元),其餘為伴侶動物;此處僅作背景,不作第二層板塊拆分。

歷史沿革

年份里程碑
1891在紐約成立,為與德國 Merck 企業相關的美國業務
1919第一次世界大戰期間遭美國政府徵收後,由 George Merck 回購,成為獨立的美國公司
1953與 Sharp & Dohme 合併,組成 Merck Sharp & Dohme
2004Vioxx 因安全疑慮在全球撤市,是重大的聲譽與財務挫折
200911月完成與 Schering-Plough 的合併,保留 Merck 之名
2014Keytruda(pembrolizumab)獲美國食品藥物管理局批准,首用於黑色素瘤
2021Robert M. Davis 於 7 月出任首席執行官,接替 Kenneth Frazier
2025Keytruda 皮下注射劑型 Keytruda Qlex 於 9 月獲美國食品藥物管理局批准,適用於 Keytruda 大多數成人實體腫瘤適應症
202510月完成 Verona Pharma 收購

競爭地位

  • 腫瘤領導地位,但集中度高。Keytruda FY2025 銷售額 $31.68B(316.8億美元),是全球最暢銷藥物之一,也是默克腫瘤業務的支柱。其免疫腫瘤主要對手是 Bristol Myers Squibb 的 Opdivo。
  • 疫苗廣度。Gardasil/Gardasil 9、ProQuad/M-M-R II/Varivax 與肺炎球菌疫苗構成龐大的預防保健業務,儘管 Gardasil FY2025 銷售額大幅下滑。
  • 研發規模。FY2025 研發支出 $15.789B(157.89億美元),橫跨腫瘤、疫苗、心臟代謝、呼吸與傳染病,支撐龐大的後期管線,包括圍繞 Keytruda 的組合療法。
  • 收購帶動更新。FY2025 以 $10.042B(100.42億美元)現金(扣除取得現金)收購 Verona Pharma,是刻意以收購上市或後期資產抵銷未來專利損失的模式,而非僅靠內部發現。
  • 競爭集合。處方藥與腫瘤領域為 Pfizer、Bristol Myers Squibb、Eli Lilly、Johnson & Johnson 與 Amgen;動物健康領域為 Zoetis 與 Boehringer Ingelheim。

財務快照 — FY2025

銷售額$65.011B(650.11億美元)(較 FY2024 增長 1.3%)
銷售成本$16.382B(163.82億美元)
毛利$48.629B(486.29億美元)· 毛利率 74.8%
研發$15.789B(157.89億美元)
銷售、一般與行政費用$10.733B(107.33億美元)
稅前利潤$21.067B(210.67億美元)
歸屬 Merck & Co., Inc. 的淨利潤$18.254B(182.54億美元)· 淨利率 28.1%
經營現金流$16.472B(164.72億美元)
資本支出$4.112B(41.12億美元)
現金及現金等值物$14.565B(145.65億美元)(2025年12月31日)
長期債務$46.750B(467.5億美元)(2025年12月31日)
來源:Merck FY2025 Form 10-K(會計年度截至2025年12月31日,2026年2月24日申報)。毛利為銷售額減銷售成本。最新季度:本稿未以經核實的 10-Q 數字列示;2026 年第三季原定於 2026 年 10 月 29 日公布,晚於 2026 年 10 月 23 日的市場數據 as-of 日期。

主要風險

  • Keytruda 集中度與專利到期。Keytruda/Keytruda Qlex 銷售額 $31.68B(316.8億美元),佔 FY2025 總銷售額 48.7%。10-K 指出,美國主要化合物專利於 2028 年 12 月到期時可能開始出現生物相似藥競爭,而默克預計在化合物專利到期後於 2031 年在歐洲失去市場獨佔權。
  • 政府定價。10-K 指出,默克預計 Keytruda 將於 2027 年被選入政府定價,定價自 2029 年 1 月 1 日起生效,屆時美國 Keytruda 銷售額將大幅下降。
  • Gardasil 下滑。Gardasil/Gardasil 9 銷售額由 FY2024 的 $8.583B(85.83億美元)降至 FY2025 的 $5.233B(52.33億美元),跌幅 39%,顯示疫苗業務可因需求與庫存模式而快速變動。
  • Januvia 與 Janumet 獨佔權喪失。10-K 指出,在 2026 年 5 月失去市場獨佔權後,默克預計將失去幾乎全部美國 Januvia 與 Janumet 銷售額。
  • 管線與交易執行。要取代 Keytruda 規模的銷售,取決於後期試驗、監管批准與收購資產的表現;僅 Verona Pharma 收購一項,FY2025 即以現金支付 $10.042B(100.42億美元)(扣除取得現金)。
  • 訴訟與監管。作為大型處方藥製造商,默克面臨專利訴訟、產品責任索賠、定價壓力,以及美國與海外醫療健康監管的變化。

對標普500的重要性

默克是醫療健康(XLV)成分股,按權重在標普500 排名 #30,權重 0.52%,在醫療健康板塊排名 #5 of 60,截至 2026 年 10 月 23 日。按此權重,MRK 單獨波動 1%,標普500 大約動 0.5 個基點,還未計入對製藥同業的連動,因此默克是板塊風向標,而非指數驅動者。

對指數觀察者而言,默克的重要性在另一層面:它是標普500 中最大的純製藥公司之一,因此其 Keytruda 週期、疫苗需求與專利到期日程,被視為整個醫療健康板塊、藥品定價政策,以及指數盈利增長中有多少繫於單一專利產品的訊號。

來源與方法

財務、板塊、員工Merck FY2025 Form 10-K(2026年2月24日申報;會計年度截至2025年12月31日)
指數權重與排名Slickcharts 標普500權重,2026年10月23日收盤,依派工基線表
Keytruda 專利與定價陳述Merck FY2025 Form 10-K,Item 1 與 Item 7 風險與專利披露
歷史里程碑既有二手報導中的公司歷史;2009 年合併與 2014 年 Keytruda 批准為廣泛報導的公開事件
LogoSPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。
市值≈$358B(2026年10月23日)

10年股價K線圖(月K)

MERCK

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · MRK
Data as of Oct 23, 2026 · Financials FY2025 (10-K) · Market data Oct 2026
Previous · Bank of America Corporation (BAC) — XLF Financials · S&P 500 Profile |美國銀行公司介紹Next · UnitedHealth Group Incorporated (UNH) — XLV Health Care · S&P 500 Profile |聯合健康集團公司介紹

Entered 2026-10-25 06:16 · updated 2026-11-14 23:50 · rev 9